{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:27:38Z","timestamp":1790346458997,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":42,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ctrv.2022.102396","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T06:12:37Z","timestamp":1651471957000},"page":"102396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee"],"prefix":"10.1016","volume":"107","author":[{"given":"H.","family":"Woopen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gleeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jhingran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kajimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mayadev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Barretina-Ginesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"van Dorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2022.102396_b0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ogc.2018.10.002","article-title":"Cancer Survivorship","volume":"46","author":"Gynecologic","year":"2019","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1016\/j.ctrv.2022.102396_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2017.03.022","article-title":"An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations","volume":"146","author":"Salani","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2022.102396_b0015","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.6004\/jnccn.2020.0037","article-title":"NCCN Guidelines Insights: Survivorship, Version 2.2020","volume":"18","author":"Denlinger","year":"2020","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102396_b0020","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s11764-020-00973-w","article-title":"Cancer survivors referred to a long-term survivorship outpatient service within academic medical oncology: descriptive study","volume":"15","author":"Gallego","year":"2021","journal-title":"J Cancer Surviv Res Pract"},{"issue":"25","key":"10.1016\/j.ctrv.2022.102396_b0025","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMra1712502","article-title":"Cancer Survivorship","volume":"379","author":"Longo","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102396_b0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11764-015-0472-9","article-title":"Survivors of gynecologic malignancies: impact of treatment on health and well-being","volume":"10","author":"Westin","year":"2016","journal-title":"J Cancer Surviv Res Pract"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102396_b0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11764-009-0093-2","article-title":"Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group","volume":"3","author":"Ganz","year":"2009","journal-title":"J Cancer Surviv Res Pract"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102396_b0040","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.ejca.2014.04.018","article-title":"Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: challenges and opportunities","volume":"50","author":"van Leeuwen","year":"2014","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ctrv.2022.102396_b0045","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ygyno.2013.05.022","article-title":"Survivorship planning in gynecologic cancer patients","volume":"130","author":"Salani","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2022.102396_b0050","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ijgo.12315","article-title":"Clinical characteristics and prognostic inflection points among long-term survivors of advanced epithelial ovarian cancer","volume":"139","author":"Son","year":"2017","journal-title":"Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet"},{"key":"10.1016\/j.ctrv.2022.102396_b0055","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2017.10.032","article-title":"Who are the long-term survivors of high grade serous ovarian cancer?","volume":"148","author":"Hoppenot","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102396_b0060","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ygyno.2016.03.010","article-title":"Characteristics of 10-year survivors of high-grade serous ovarian carcinoma","volume":"141","author":"Dao","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102396_b0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-018-0920-0","article-title":"Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire","volume":"16","author":"van Leeuwen","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ctrv.2022.102396_b0070","doi-asserted-by":"crossref","first-page":"viii335","DOI":"10.1093\/annonc\/mdy285.148","article-title":"Quality of life and symptoms in longterm survivors with ovarian cancer: It\u2019s still an issue. Expression VI \u2013 Carolin meets HANNA \u2013 holistic analysis of long-term survival with ovarian cancer: The international NOGGO, ENGOT and GCIG survey","volume":"29","author":"Woopen","year":"2018","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.ctrv.2022.102396_b0075","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1200\/JCO.2009.22.5151","article-title":"Patients\u2019 supportive care needs beyond the end of cancer treatment: a prospective, longitudinal survey","volume":"27","author":"Armes","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102396_b0080","first-page":"5045","article-title":"Quality of life and sexuality of patients after treatment for gynaecological malignancies: results of a prospective study in 55 patients","volume":"32","author":"Pilger","year":"2012","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102396_b0085","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ygyno.2011.10.030","article-title":"Informational needs of gynecologic cancer survivors","volume":"124","author":"Papadakos","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2022.102396_b0090","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102396_b0095","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00066-017-1143-8","article-title":"General health status of long-term cervical cancer survivors after radiotherapyAllgemeiner Gesundheitsstatus Langzeit\u00fcberlebender von Geb\u00e4rmutterhalskrebs nach Strahlentherapie","volume":"193","author":"Sung Uk","year":"2017","journal-title":"Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al"},{"key":"10.1016\/j.ctrv.2022.102396_b0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.clinthera.2014.11.013","article-title":"Cervical cancer survivorship: long-term quality of life and social support","volume":"37","author":"Pfaendler","year":"2015","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102396_b0105","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ygyno.2012.12.033","article-title":"Quality of life in long-term cervical cancer survivors: a population-based study","volume":"129","author":"Le Borgne","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2022.102396_b0110","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.radonc.2014.04.011","article-title":"Second primary cancers in survivors of cervical cancer in The Netherlands: Implications for prevention and surveillance","volume":"111","author":"Arnold","year":"2014","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ctrv.2022.102396_b0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ygyno.2010.02.027","article-title":"Surviving cervical cancer: does health-related quality of life influence survival?","volume":"118","author":"Ashing-Giwa","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2022.102396_b0120","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/AOG.0000000000000981","article-title":"Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer","volume":"126","author":"Cress","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102396_b0125","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ijgc-2020-002023","article-title":"Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis","volume":"31","author":"Baum","year":"2021","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ctrv.2022.102396_b0130","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1200\/JCO.2006.09.1769","article-title":"Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones?","volume":"25","author":"Liavaag","year":"2007","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102396_b0135","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/annonc\/mdz074","article-title":"Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case\/control VIVROVAIRE I study","volume":"30","author":"Joly","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102396_b0140","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ygyno.2019.08.009","article-title":"OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors","volume":"155","author":"Webber","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102396_b0145","doi-asserted-by":"crossref","first-page":"12065","DOI":"10.1200\/JCO.2020.38.15_suppl.12065","article-title":"Fatigue in long-term survivors with ovarian cancer: Results of Expression VI \u2013 Carolin meets HANNA \u2013 Holistic analysis of Long-term survival with ovarian cancer\u2014The international NOGGO, ENGOT and GCIG survey","volume":"38","author":"Woopen","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102396_b0150","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2014.09.016","article-title":"Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry","volume":"135","author":"Ezendam","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2022.102396_b0155","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3109\/13697137.2014.929104","article-title":"Sexual activity and functioning in ovarian cancer survivors: an internet-based evaluation","volume":"18","author":"Hopkins","year":"2015","journal-title":"Climacteric J Int Menopause Soc"},{"key":"10.1016\/j.ctrv.2022.102396_b0160","doi-asserted-by":"crossref","unstructured":"Rolf C, Woopen H, Richter R, Sehouli AP, Braicu EI, Schnuppe K, et al. Assessment of sexuality in longterm survivors with ovarian cancer. Geburtshilfe Frauenheilkd., vol. 78, Georg Thieme Verlag KG; 2018, p. P 110. Doi: 10.1055\/s-0038-1671329.","DOI":"10.1055\/s-0038-1671329"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102396_b0165","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ygyno.2021.10.001","article-title":"Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study","volume":"163","author":"Gernier","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2022.102396_b0170","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/ijgc-2018-000040","article-title":"Causes of death among women with epithelial ovarian cancer by length of survival post-diagnosis: a population-based study in British Columbia, Canada","volume":"29","author":"Arora","year":"2019","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ctrv.2022.102396_b0175","first-page":"1564","article-title":"Second malignant neoplasms among long-term survivors of ovarian cancer","volume":"56","author":"Travis","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102396_b0180","doi-asserted-by":"crossref","first-page":"513","DOI":"10.5604\/12321966.1232759","article-title":"Quality of life in long-term survivors of early stage endometrial cancer","volume":"24","author":"Dobrzycka","year":"2017","journal-title":"Ann Agric Environ Med AAEM"},{"key":"10.1016\/j.ctrv.2022.102396_b0185","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/IGC.0000000000000905","article-title":"Sexual Function and Quality of Life Among Patients With Endometrial Cancer After Surgery","volume":"27","author":"Gao","year":"2017","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ctrv.2022.102396_b0190","first-page":"1342","article-title":"Long-term cardiovascular outcomes among endometrial cancer survivors in a large, population-based cohort study","volume":"110","author":"Soisson","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102396_b0195","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ygyno.2017.12.025","article-title":"Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study","volume":"148","author":"Soisson","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"124","key":"10.1016\/j.ctrv.2022.102396_b0200","first-page":"142","article-title":"Increased risk for second primary rectal cancer after pelvic radiation therapy","volume":"2020","author":"Rombouts","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ctrv.2022.102396_b0205","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1002\/ijc.30930","article-title":"Risk of second primary cancers in women diagnosed with endometrial cancer in German and Swedish cancer registries","volume":"141","author":"Chen","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2022.102396_b0210","first-page":"CD012529","article-title":"Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers","volume":"1","author":"Lawrie","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2022.102396_b0215","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.brachy.2020.12.008","article-title":"Interstitial brachytherapy for gynecologic malignancies: Complications, toxicities, and management","volume":"20","author":"Kamrava","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ctrv.2022.102396_b0220","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ejogrb.2017.01.025","article-title":"The future for follow-up of gynaecological cancer in Europe. Summary of available data and overview of ongoing trials","volume":"210","author":"Leeson","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102396_b0225","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/ijgc-2019-001176","article-title":"British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU)","volume":"30","author":"Newton","year":"2020","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102396_b0230","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ygyno.2020.06.492","article-title":"Risk of second primary cancers among survivors of gynecological cancers","volume":"158","author":"Adjei Boakye","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102396_b0235","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/ijgc-2020-002155","article-title":"Secondary malignancies in long-term ovarian cancer survivors: results of the \u201cCarolin meets HANNA\u201d study","volume":"31","author":"Woopen","year":"2021","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"issue":"21","key":"10.1016\/j.ctrv.2022.102396_b0240","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/jnci\/djm201","article-title":"Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk","volume":"99","author":"Chaturvedi","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2022.102396_b0245","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bpobgyn.2020.01.005","article-title":"Genetic testing for epithelial ovarian cancer","volume":"65","author":"Amin","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102396_b0250","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ygyno.2021.10.077","article-title":"Breast cancer surveillance following ovarian cancer in BRCA mutation carriers","volume":"164","author":"John","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102396_b0255","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ygyno.2017.02.032","article-title":"Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?","volume":"145","author":"McGee","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102396_b0260","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ygyno.2020.09.006","article-title":"Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16\/NOVA trial","volume":"159","author":"Mirza","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102396_b0265","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2022.102396_b0270","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102396_b0275","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1136\/ijgc-2019-001070","article-title":"Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment","volume":"30","author":"Armbrust","year":"2020","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102396_b0280","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ygyno.2020.10.023","article-title":"GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function","volume":"160","author":"Carter","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2022.102396_b0285","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/ijgc-2019-001032","article-title":"Lower extremity lymphedema in patients with gynecologic malignancies","volume":"30","author":"Dessources","year":"2020","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ctrv.2022.102396_b0290","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/micr.20737","article-title":"Microsurgery for lymphedema: clinical research and long-term results","volume":"30","author":"Campisi","year":"2010","journal-title":"Microsurgery"},{"key":"10.1016\/j.ctrv.2022.102396_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102831","article-title":"Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings","volume":"145","author":"Ibrahim","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102396_b0300","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/cncr.32807","article-title":"Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women","volume":"126","author":"Salcedo","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2022.102396_b0305","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.maturitas.2020.08.010","article-title":"Genitourinary Syndrome of Menopause: Current Treatment Options in Breast Cancer Survivors - Systematic Review","volume":"143","author":"Mension","year":"2021","journal-title":"Maturitas"},{"key":"10.1016\/j.ctrv.2022.102396_b0310","first-page":"CD012559","article-title":"Hormone replacement therapy after surgery for epithelial ovarian cancer","volume":"1","author":"Saeaib","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2022.102396_b0315","first-page":"CD008830","article-title":"Hormone replacement therapy for women previously treated for endometrial cancer","volume":"5","author":"Edey","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2022.102396_b0320","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.3390\/jcm10143165","article-title":"Hormone Replacement Therapy in Endometrial Cancer Survivors: A Meta-Analysis","volume":"10","author":"Londero","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102396_b0325","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ygyno.2020.01.035","volume":"157","author":"Sinno","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2022.102396_b0330","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.maturitas.2020.01.005","article-title":"European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis","volume":"134","author":"Rees","year":"2020","journal-title":"Maturitas"},{"key":"10.1016\/j.ctrv.2022.102396_b0335","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1080\/13697137.2019.1606796","article-title":"Sexual function after cancer: paying the price of survivorship","volume":"22","author":"Bober","year":"2019","journal-title":"Climacteric J Int Menopause Soc"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102396_b0340","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00192-021-04798-8","article-title":"Vaginal stenosis in women with cervical or endometrial cancer after pelvic radiotherapy: a cross-sectional study of vaginal measurements, risk for sexual dysfunction and quality of life","volume":"33","author":"de Morais Siqueira","year":"2022","journal-title":"Int Urogynecology J"},{"key":"10.1016\/j.ctrv.2022.102396_b0345","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.maturitas.2020.10.018","article-title":"Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors","volume":"144","author":"Quick","year":"2021","journal-title":"Maturitas"},{"key":"10.1016\/j.ctrv.2022.102396_b0350","first-page":"459","article-title":"Pelvic floor disorders in women with gynecologic malignancies: a systematic review","volume":"29","author":"Ramaseshan","year":"2018","journal-title":"Int Urogynecology J"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102396_b0355","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrclinonc.2012.99","article-title":"Reducing the toxicity of cancer therapy: recognizing needs, taking action","volume":"9","author":"Cleeland","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102396_b0360","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ygyno.2018.01.034","article-title":"Ongoing strategies and updates on pain management in gynecologic oncology patients","volume":"149","author":"Hacker","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2022.102396_b0365","unstructured":"Woopen H, Keller M, Braicu EI, Zocholl D, Krabisch P, Boxler T, et al. Fatigue in long-term survivors with ovarian cancer: Results of Expression VI \u2013 Carolin meets HANNA \u2013 Holistic analysis of Long-term survival with ovarian cancer\u2014The international NOGGO, ENGOT and GCIG survey. n.d."},{"key":"10.1016\/j.ctrv.2022.102396_b0370","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/PPO.0000000000000396","article-title":"Integrative Therapies for Cancer-Related Fatigue","volume":"25","author":"Arring","year":"2019","journal-title":"Cancer J Sudbury Mass"},{"key":"10.1016\/j.ctrv.2022.102396_b0375","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","article-title":"Cancer-related fatigue\u2013mechanisms, risk factors, and treatments","volume":"11","author":"Bower","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102396_b0380","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ygyno.2015.10.003","article-title":"Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology\/gynecologic oncology group study","volume":"139","author":"Hess","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102396_b0385","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/jso.25374","article-title":"Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies","volume":"120","author":"Lentz","year":"2019","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2022.102396_b0390","doi-asserted-by":"crossref","DOI":"10.1111\/ecc.13057","article-title":"A systematic literature review of trials of survivorship interventions for women with gynaecological cancer and their caregivers","volume":"28","author":"Beesley","year":"2019","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102396_b0395","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s11764-020-00946-z","article-title":"Patient-reported outcomes of non-pharmacological interventions for endometrial cancer survivors: a systematic review","volume":"15","author":"Buchanan","year":"2021","journal-title":"J Cancer Surviv Res Pract"},{"key":"10.1016\/j.ctrv.2022.102396_b0400","doi-asserted-by":"crossref","first-page":"784","DOI":"10.6004\/jnccn.2019.0034","article-title":"Survivorship, Version 2.2019","volume":"17","author":"Sanft","year":"2019","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102396_b0405","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1634\/theoncologist.2019-0184","article-title":"Survivorship Care Plans in Cancer: A Meta-Analysis and Systematic Review of Care Plan Outcomes","volume":"25","author":"Hill","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2022.102396_b0410","first-page":"554","article-title":"Langzeit\u00fcberlebende mit bzw. nach Ovarialkarzinom \u2013 eine Herausforderung. Kongressbericht und kritische Diskussion der aktuellen Datenlage","volume":"08","author":"Woopen","year":"2020","journal-title":"Frauenarzt"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102396_b0415","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s11764-018-0713-9","article-title":"Survivorship care planning in gynecologic oncology-perspectives from patients, caregivers, and health care providers","volume":"12","author":"de Rooij","year":"2018","journal-title":"J Cancer Surviv Res Pract"}],"updated-by":[{"DOI":"10.1016\/j.ctrv.2022.102431","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000}}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222000603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222000603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T13:50:08Z","timestamp":1727099408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222000603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":83,"alternative-id":["S0305737222000603"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102396","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ctrv.2022.102431","asserted-by":"object"}]},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102396","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102396"}}